$OSCR

Liang Janet sold $274K of OSCR

Liang Janet (President, Oscar Insurance) sold 12,475 shares of Oscar Health, Inc. (OSCR) at an average of $21.94 ($21.74–$22.45, $0.27M total) across 2 trades on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Liang Janet
Published Jun 4, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

The disclosed sale reduces insider ownership but is unlikely to materially affect the company's fundamentals.

02

Market read

A modest insider sell via a pre‑arranged plan, offering limited trading relevance.

03

What to watch

Potential upcoming earnings or strategic announcements that may offset the sell pressure.

Relevance 3/10Novelty 3/10Timing: post‑market filing on 2026‑06‑04

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale by a senior executive is a standard compliance disclosure.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

President Janet Liang sold 12,475 shares for $273,716 via a 10b5-1 plan, reducing her stake to 259,057 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

Sale size is modest ($274K) and disclosed via a Form 4, which typically leads to short‑term downside bias.

Market effects

Minimal impact on the health‑insurance sector; insider sales are routine.

No broader regional effect.

Limited to Oscar Health investors.

Counterpoint

The sale could be a routine liquidity move and not indicative of future weakness.

Key entities

  • Oscar Health, Inc.

    U.S. health‑insurance provider listed on NASDAQ.

  • Janet Liang

    President of Oscar Insurance, insider selling shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.